The Senior Vice President of Danaher and Delegation Visited CytoNiche to Discuss New Future of Cell Therapy and Scalable Production

Date : 2025-09-28

Publisher : Cytoniche | Marketing

We look forward to continued collaboration and dialogue with visionary leaders like Danaher as we work together toward building a more sustainable global CGT ecosystem.

BEIJING, September 19, 2025--Dr. Jose-Carlos Gutiérrez-Ramos, Senior Vice President and Chief Scientific Officer of Danaher, a leading global life sciences and diagnostics innovator, visited BEIJING CYTONICHE BIOTECH CO., LTD. with his team. Both sides focused on cutting-edge trends in biotechnology and innovations in cell-scale preparation processes, engaging in in-depth discussions on topics such as technological collaborative research and core business layout.

During the exchange, Dr. Yan Xiaojun, Co-founder & CTO of CytoNiche, introduced the company's situation to the attendees and systematically explained the core advantages of its 3D cell-scale culture technology system. Addressing the pain points of traditional two-dimensional culture processes, such as scaling bottlenecks, batch quality fluctuations, and high production costs, CytoNiche' s independently developed 3D TableTrix^TM & 3D RecomTrix^TM , porous microcarriers dissolvable achieves stable amplification and cost optimization of stem cell drug industrial production through innovative material design and automated control, and has completed commercial verification in the Chinese market. During the visit, both sides conducted in-depth discussions focusing on global market expansion of microcarrier technology, product iteration and upgrading, as well as collaborative layout of the industrial chain.

The visiting guests also included Harvard University professor and member of the National Academies of Science, David R. Walt, along with several leaders from Danaher’s global and China pharmaceutical technology and scientific innovation business sectors. Accompanied by Dr. Yan Xiaojun, the guests toured the company's exhibition hall and research and development center, gaining an intuitive understanding of CytoNiche’ s innovative achievements in 3D cell single-use, closed, large-scale preparation processes. They highly praised CytoNiche’ s capabilities in process standardization, quality system control, and scalability in production.

This exchange provided a new opportunity for CytoNiche to advance international technological cooperation and expand global market applications. As a core representative enterprise for the transformation of scientific and technological achievements from Tsinghua University, the company is committed to promoting the standardization and scaling development of the cell and gene therapy (CGT) industry. In the future, CytoNiche will continue to deepen its technological cooperation with global top enterprises, accelerating breakthroughs in the industrial production technology bottleneck of cell therapy, and assisting the global CGT industry in achieving high-quality, sustainable development.